Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Venetoclax + Obinutuzumab +/- Acalabrutinib for Chronic Lymphocytic Leukemia
Recruiting3 awardsPhase 2
Boston, Massachusetts
This trial is testing a combination of drugs to see if they are effective in treating CLL or SLL. The drugs involved are obinutuzumab, venetoclax, and acalabrutinib.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service